Asarina Pharma CEO Peter Nordkild will present the company’s positive results from its Phase IIa study of Sepranolone for Tourette Syndrome at events in May and June 2023 in Europe and the US. See the schedule here.
May 19: Assoc. Prof. Marco Bortolato (Dept Pharmacology & Toxicology, University of Utah) presents Asarina Pharma’s Phase IIa results at TicCon – the Virtual National Conference of the Tourette Association of America, at 9.30 PM CET. His presentation is titled: ‘Putative novel pharmacological treatments for tic disorders’. Register here: https://touretteconference.org/en/registration
June 5-8: CEO and Business Development Officer Otto Skolling attend BIO 2023, Boston International Convention Center, Boston Mass. US. Register here: https://www.bio.org/events/bio-international-convention
June 7-9: CEO Peter Nordkild presents the full Phase IIa data at EESTS, the 15th European Conference on Tourette Syndrome and Tic Disorders in Brussels Belgium. Register for the event here: https://www.essts.org/registration